UK clinical AI technology company,announced on Thursday that it had extended its existing collaboration with multinational pharmaceutical firm, Bayer, for the development of new treatments using clinical AI.
Sensyne will partner with Bayer’s division, LifeHub UK, which makes up a wider network of global innovation hotspots with the aim of catalysing impactful solutions at the intersection of health and nutrition.
Specifically, the division, which launches today, is designed to streamline disease detection as well as data-driven drug discovery with the aid of AI-enabled imaging solutions.
Commenting on the extended collaboration, CEO of Sensyne Health, Lord Paul Drayson explained, "Initiatives like this are essential to quickly maximise the opportunity AI presents to improve patient care and accelerate medical research.”
Sensyne will be one of the first companies to establish a presence in the LifeHub, with the first project focusing on radiology solutions using the firm’s AI technology platform in order to identify digital solutions for automated image evaluation.
The project will analyse research from three million anonymised, ethically sourced NHS patient records and data provided through Sensyne’s partnerships with NHS trusts, with the NHS remaining the controller of all patient data.
Essentially, Sensyne will act as a ‘docking station’ for anonymised patient data analysis under strict oversight from the NHS trust, the company emphasised -- this will ensure ethical governance is practiced under NHS principles, EU data protection law and regulatory guidance.
Kemal Malik, a Bayer Board Member for Innovation, expressed his delight at the programme, stating that its launch reflected a firm belief in the transformative potential of AI in healthcare, he commented:
"LifeHub UK's roadmap is a perfect fit to Bayer's Open Innovation strategy, which is designed to leverage places, programmes and partnerships - such as strategic alliances and joint ventures - in the life sciences fields of pharmaceuticals and agriculture."
Additionally, the firm revealed its intentions to conduct further joint R&D activities with Bayer to further advance imaging solutions using AI.
Follow News & Updates from Sensyne Health here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
The group had carried a preliminary analysis of data from the Geological Survey of Ireland’s 'Tellus' airborne geophysical survey, revealing previously unknown and prospective geological features at the site of which Arkle holds a 23.44% interest in.
SP Angel research note on commdities and miners, featuring: Anglo American (AAL LN) – De Beers diamond sales Arc Minerals* (ARCM LN) – Arc sells Casa Mining to focus on Cheyeza copper discovery Aura Energy Limited* (AURA LN) – Cost reduction programme Bushveld Minerals* (BMN LN) – Bushveld Energy leading consortium for acquisition of Enerox from CellCube for €11m Caledonia Mining (CMCL LN) – Robust performance despite challenges of power supply Horizonte Minerals (HZM LN) – Quarterly results and project update. SolGold* (SOLG LN) – Ingo Hofmaier takes over London office following resignation of Anna Legge
Stephen Blyth, Chief Executive Officer of Xpediator, said: "I am delighted Robert is joining us. He is a talented individual and comes to us from an industry peer of a similar size which ensures he has an excellent understanding of our markets and the future opportunities within them.”
The group’s Hardide-A coating was approved after extensive testing demonstrated that its use would be suited for the aircraft’s drag chute components for the F-35A CTOL (conventional take-off and landing) variant.
The successful construction and delivery of the reactors and catalyst order further adds to positive ongoing work that Velocys us performing both in the UK and the United States on its flagship projects.
The Rugby World Cup and dating show Love Island helped bolster viewing figures and advertising revenue at ITV over the past three months, Vodafone Group has written off the entire value of its troubled Indian offshoot, sending the mobile phone provider to a €1.9 billion loss and raising questions about the ability of overseas investors to do business in the world’s second most populous nation